Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Hisamitsu Pharmaceutical Co ( (JP:4530) ) is now available.
Hisamitsu Pharmaceutical has withdrawn its consolidated earnings forecast for the fiscal year ending February 28, 2026, which had previously projected net sales of ¥165 billion and profit attributable to owners of parent of ¥22 billion. The company’s decision follows a board resolution to support a management buyout via a tender offer by Taiyo Kosan Co., Inc., recommend that shareholders tender their shares, and proceed on the assumption that its shares will be delisted. Because the former forecast incorporated gains from planned sales of cross-shareholdings and that sale policy has become undecided in light of the tender offer and expected delisting, management now considers it impossible to reasonably estimate current-year performance and has therefore withdrawn its guidance.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen4677.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc., based in Tosu City, Saga Prefecture, is a Japanese pharmaceutical company best known for developing and marketing prescription and over-the-counter medicines, including topical patches, for domestic and international markets.
Average Trading Volume: 183,552
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen328.3B
See more data about 4530 stock on TipRanks’ Stock Analysis page.